Klinische studies niertumoren

Op deze pagina



Fase 1/2 - advanced solid tumors NSCLC + RCC 


MK6482 - 011 

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After 1 Prior Anti-PD-1/L1 Combination Regimen


CHECKMATE 214 CA209-214

A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma


A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti−PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy

MK6482 – 013

Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma

Laatste aanpassing: 12 april 2023